Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely used tool for decision-making, has well-known limitations, including the assessment of plaque burden, accurate determination of the severity of calcification, definition of lesion length and borders, and, most importantly, optimization of stent implantation.

In this context, intravascular imaging (IVI—IVUS or OCT) has been shown to reduce the incidence of major adverse cardiovascular events (MACE) compared with angiography alone. However, the consistency of this benefit across different subgroups of complex lesions had not been systematically evaluated.

The aim of the study by Carvalho PEP et al. was to evaluate the impact of IVUS and OCT as guidance strategies for PCI with drug-eluting stents, compared with conventional angiography, in patients with complex coronary lesions. To this end, a lesion-level network meta-analysis was performed. Complex lesions included left main coronary artery disease, chronic total occlusions, true bifurcations, multivessel disease, ostial lesions, and moderately or severely calcified lesions. The primary endpoint was the incidence of MACE, defined as cardiac death, myocardial infarction, or target vessel revascularization.

Read also: Is upper-limb aerobic training an effective alternative to lower-limb exercise in peripheral artery disease?

Seventeen randomized studies were included, representing a total of 13,751 patients who underwent PCI. The use of IVUS was associated with a significant reduction in the relative risk of MACE (RR: 0.67; 95% CI: 0.56–0.79; p<0.001), while OCT showed a similar benefit (RR: 0.63; 95% CI: 0.55–0.72; p<0.001). No significant differences were observed between IVUS and OCT (RR: 0.94; 95% CI: 0.78–1.14; p=0.52).

Study results: IVUS and OCT reduce MACE compared with angiography in complex coronary lesions

The benefit of IVI-guided PCI was consistent across all analyzed subgroups. In left main coronary artery disease, both IVUS (RR: 0.52; 95% CI: 0.33–0.86; p=0.02) and OCT (RR: 0.51; 95% CI: 0.30–0.86; p=0.01) significantly reduced events. In chronic total occlusions, IVUS was associated with a significant reduction in MACE (RR: 0.57; 95% CI: 0.37–0.88; p=0.01). In bifurcations, moderately or severely calcified lesions, long lesions, and multivessel disease, both imaging techniques were associated with a significant reduction in events compared with coronary angiography, without relevant differences between IVUS and OCT (with respective RRs of 0.83, 0.92, 0.81, and 1.27).

Sensitivity analyses confirmed these findings, showing a significant reduction in MACE for both IVUS (HR: 0.47; 95% CI: 0.36–0.61) and OCT (HR: 0.56; 95% CI: 0.40–0.80). In addition, the strategy ranking analysis using the P score consistently positioned angiography as the least favorable option, while IVUS and OCT alternated first place depending on lesion subtype. IVUS ranked higher in bifurcations and long lesions, whereas OCT ranked higher in multivessel disease.

Read also: Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Conclusions: the central role of IVUS and OCT in optimizing complex coronary angioplasty

Both IVUS and OCT demonstrated consistent benefits of similar magnitude, with no significant differences between the two techniques in the overall analysis. These results reinforce the central role of intravascular imaging in procedural optimization and in improving medium- and long-term clinical outcomes.

Original Title: IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions. Network Meta-Analysis of Randomized Controlled Trials.

Reference: Carvalho PEP, Antunes VLJ, Bittar de Pontes V, Gomes WF, Polachini Assunes Goncalves B, Caixeta A, Strepkos D, Alexandrou M, Mutlu D, Gibson CM, Stone GW, Bhatt DL, Windecker S, Patel MR, Angiolillo D, Mehran R, Valgimigli M, Costa MA, Sandoval Y, Brilakis ES, Lopes RD, Nascimento BR. IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2026 Jan 12;19(1):31-43. doi: 10.1016/j.jcin.2025.11.021. PMID: 41534986.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...